ERBB2 and neoplasm: The PREDICT breast prognostication and treatment benefit model is based on age at diagnosis, mode of detection, tumour size, tumour grade, number of positive lymph nodes and expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and the marker of proliferation Kiel 67 (KI67) [1, 2].